Clinical Report and Genetic Analysis of a Patient With Congenital Hyperinsulinism Hyperammonemia Caused by a Novel Missense Mutation in the Structural Domain of the Isoform of the GLUD1 Gene Authors: Tingyu Li, Tianyi Liu, Lujuan Li, Yang Liu, Qi Zhang, Xian Cheng, Zhong Li Published: 2026 ABSTRACT ABSTRACTThe patient presented with severe hypoglycemia and convulsions 43 h after birth. The clinical features were typical, with the presence of obvious hyperinsulinemic hypoglycemia and asymptomatic hyperammonemia, and it was sensitive to the treatment of diazoxide. The diagnosis of HI/HA was confirmed by genetic testing. Introduction Hyperinsulinism‐hyperammonaemia (HI/HA) (OMIM 606762) is a dominantly inherited disorder caused by mutations in the GLUD1 gene (located on chromosome 10q23.3), which encodes glutamate dehydrogenase (GDH) on the mitochondria of β‐cells [1, 2], which is the second most common type of congenital hyperinsulinism (CHI), in which patients usually present with recurrent episodes of frequent hypoglycemia and asymptomatic persistent mildly elevated blood ammonia concentrations, and 43% of patients may present with seizure symptoms [3, 4, 5, 6]. Studies have shown that this disorder is caused by mutations in the GLUD1 gene, which encodes the enzyme glutamate dehydrogenase (GDH) in the mitochondria, and is therefore also known as glutamate dehydrogenase‐type hyperinsulinemia (GDH‐HI) [3]. Most of the pathogenic variants in the GLUD1 gene are clustered in exons 6, 7, 11, and 12, and one of the hotspots for mutation is the G499 locus, which is located on exon 12 of the GLUD1 gene. The patient reported in the paper is the G499C type mutation, and we obtained complete clinical and genetic information of the patient from a patient diagnosed with HI/HA, performed whole exome sequencing (WES) on his parents as well, and carried out further analysis of the stability of the genetic variants. Case History and Examination A timeline diagram depicting major clinical events is shown as Figure 1. Timeline diagram of major clinical events. The patient was a male infant of 40 weeks gestational age, G1P1, with a birth weight of 3900 g and a body length of 51 cm. His birth weight was between the 75th and 90th percentiles for neonates, consistent with an appropriate for gestational age infant (AGA). The patient's postnatal APGAR scores were 10, 10, and 10, respectively. There was no history of asphyxia or resuscitation. Formula feeding was given 2 h after birth, with 40 mL per feed, and feeding every 2–3 h. The patient developed convulsions 43 h after birth, which manifested as bilateral lower limb shaking that lasted about 20 s and was relieved by stimulation of the soles of the feet. Meanwhile, terminal blood glucose was monitored at 1.8 mmol/L (reference range 2.5–5.0 mmol/L), and 10% dextrose injection was administered intravenously at a dose of 2 mL/kg (titration rate 1 mL/min), and blood glucose was monitored at 2.6 mmol/L one hour later. The patient's intravenous blood glucose during his hospitalization was at a minimum of 1.30 mmol/L, and he manifested recurrent episodes of refractory hypoglycemia. Insulin levels were monitored during hypoglycemia at a maximum of 850.71 pmol/L (reference range 16.5–83.23 pmol/L), C‐peptide levels at a maximum of 6258.91 pmol/L (reference range 260–1729 pmol/L), and blood ammonia levels at a maximum of 111 μmol/L (reference range 9–30 μmol/L). The patient's liver function tests, triglycerides, cholesterol, and uric acid tests were normal. No electrolyte disturbance was observed. Routine blood tests, cortisol levels, and thyroid function tests were all normal. The mother had normal blood glucose levels during pregnancy and no history of gestational diabetes mellitus. Therefore, neonatal hypoxic–ischemic encephalopathy, neonatal sepsis, perinatal stress factors, and endocrine deficiency diseases were ruled out, and congenital hyperinsulinism (CHI) was highly suspected. The relevant test results during the patients' hospitalization are shown in Table 1. The patient's cardiac ultrasound and cranial ultrasound showed no abnormality, MRI of the head showed mild edema of the cerebral white matter, and enhanced CT of the pancreas showed no abnormality. TABLE 1Results of relevant tests during the patient's hospitalization.Inspection indicatorsReference rangeD1D2D3D5D8WBC15–20 × 109/L13.28NANA16.98NANEUT%31%–40%79.1NANA61.2NALYMPH%40%–60%11.4NANA15.2NAHGB180–190 g/L214NANA181NAPLT125–400 × 109/L193NANA253NACRP0–10 mg/L< 0.80NANA< 0.80NAMinimum glucose level GLU2.5–5.0 mmol/L1.81.32.73.21.8Glycated hemoglobin4.0%–6.1%NA5.2NANANASerum insulin16.5–83.23 pmol/LNA850.71NANA68.74C‐peptide260–1729 pmol/LNA6258.91NANA2740.02Serum ammonia9–30 μmol/LNA108NANA111Plasma cortisol am:138–690 μmol/L Pm:69–345 μmol/L NAam:189.0NANANASerum adrenocorticotropic hormone (SAT)< 46 pg/mLNA40.3NANANAGrowth hormone measurement0–3 μg/dLNA3.74NANANAT31.23–4.22 nmol/LNA2.08NANA1.84T469.9–219 nmol/LNA198.04NANA136.92FT33–9.28 pmol/LNA5.50NANA5.19FT49.0–28.3 pmol/LNA24.28NANA16.00TSH0.72–11mIU/LNA21.975NANA5.375 Note: NA means the item is not detected. Results of relevant tests during the patient's hospitalization. am:138–690 μmol/L Pm:69–345 μmol/L Note: NA means the item is not detected. Differential Diagnosis, Investigations and Treatment Mutation testing is the standard diagnostic modality for congenital hyperinsulinemia, and in some cases it may be necessary to use next‐generation sequencing to rule out large genetic defects or recessive mutations [7]. We performed whole‐exome sequencing of blood samples from preexisting subjects and their parents to identify potential genetic defects. Sequenced fragments were aligned to the UCSC hg19 human reference genome by BWA to remove duplicates. The protein structures of GLUD1 and mutant GLUD1 were predicted using Alphafold 2.3.2 developed by DeepMind [8]. Identification of Mutations in the GLUD1 Gene (Genetic Variant Detection Analysis) The patient's parents were non‐consanguineous and had no family history of hypoglycemia or other related inherited metabolic disorders (see Figure 2). By whole exome sequencing of the patient and her parents, a pathogenic variant associated with the subject's phenotype was detected in the GLUD1 gene associated with familial hyperinsulinemia type 6, i.e., the GLUD1; NM_005271.3:c.1495G>T(p.Gly499Cys) variant. This patient had a G to T mutation in the nucleic acid sequence base at position 1495, resulting in a change in amino acid from glycine to cysteine at position 499 (exon 12 region). Exome‐wide genetic testing showed that neither of the patient's parents had a similar mutation, and Sanger sequencing confirmed that the mutation was de novo and there was no family history of the mutation (verified by both parents) (shown in Figure 3). No other variants associated with the clinical phenotype were detected. This test was analyzed by high‐throughput data information analysis, and no pathogenic chromosomal CNV variants above 1 M and LOH variants above 5 M associated with the phenotype of the prevalent patients were detected. The ClinVar database was accessed via the NCBI (National Center for Biotechnology Information) website, and no record of this variant was found. The databases and their versions queried are as follows: ESP6500 (V2), 1000 Genomes Project (Phase 3), ExAC (r0.3.1), and GnomAD (r2.0.1). Genealogy of the first witnesses. Sanger sequences of subject families, mutation sites are indicated by red arrows (c.1495G>T(p.Gly499Cys)). Pathogenicity Analysis and Mutation Prediction of the Variant Locus According to the American College of Medical Genetics and Genomics Guidelines (ACMG Guidelines) [9], this variant was determined to be a pathogenic variant, PS2 + PS4_Supporting + PM1 + PM2 + PP4. (PS2: de novo variant in the patient with no family history (verified by both parents).) PS4_Supporting: PS4 degradation. PM1: located in hotspot mutation regions, and/or located in key functional domains that are known to be free of benign variants. PM2: variants not found in normal control populations in the ESP database, Thousands database, or EXAC database (or very low‐frequency loci in recessive genetic disorders). PP4: variant carriers with phenotypes or family histories that are highly consistent with a single‐gene inherited disease. PP4_Supporting: variants that are new to the patient, and with no family history (verified by both parents). Using the online software tools SIFT (https://sift.bii.a‐star.edu.sg/), Polyphen‐2 (www.genetics.bwh.harvard.edu/pph2) and MutationTaster (www.mutationtaster.org) for mutation prediction, the predicted hazard values of the SIFT algorithm were < 0.05 (disruptive), Polyphen2_HumDiv was 0.988 (disruptive), Polyphen2_HumVar was 0.790 (disruptive), and MutationTaster was 1 (causative), which suggests that this mutation is deleterious. Molecular Dynamics Simulation Results In this study, the three‐dimensional structures of wild‐type GLUD1 and mutant GLUD1 proteins were predicted using alphafold 2.3.2, and the changes in the RMSD during the simulation process were calculated by molecular dynamics simulation to analyze the changes in the structural stability of the mutated GLUD1 protein, as shown in Figure 4a. If the RMSD value of the protein fluctuates less during the whole simulation process and can reach equilibrium (amplitude less than 2 Å) in a short time, the protein structure can be considered as relatively stable. On the contrary, if the RMSD value fluctuates greatly or the complex fails to reach equilibrium throughout the simulation (RMSD fluctuates continuously and the amplitude is greater than 2 Å), then the structure of the protein may be unstable. In this study, the stability of the protein was analyzed by calculating the RMSD value of the 100 ns MD simulation trajectory. As shown in Figure 4b, after 20 ns of simulation, the RMSD value of wild‐type GLUD1 fluctuates with amplitude less than 2 Å, and the RMSD value of the mutant type fluctuates continuously and does not reach the equilibrium state within 100 ns of simulation time. The above structure suggests that the G499C‐type mutation may have a significant impact on the structural stability of GLUD1. It also illustrates from another perspective that the mutation may have an impact on the biological function of GLDU1. Molecular dynamics simulation analysis of GLUD1 wild‐type and G499C mutant proteins. (A) Schematic representation of the GLUD1 protein structure and the G499C mutation. The red circle highlights the location of residue 499 in the GLUD1 protein. The magnified view shows the side‐chain structural change from glycine (GLY‐499) in the wild‐type protein to cysteine (CYS‐499) in the mutant. (B) RMSD plot of the backbone atoms of wild‐type GLUD1 (black line) and the G499C mutant (red line) over the 100 ns MD simulation. Treatment 10% glucose was injected to raise the blood sugar of the patient. When the sugar rate was greater than 12 mg/kg/min, hypoglycemia still existed. Hydrocortisone was then administered at a dose of 7 mg/kg every 6 h. However, blood glucose stability was not achieved after 7 days of treatment. The patient was coadministered with diazoxide (5 mg/kg/d was gradually increased to 10 mg/kg/d), and hydrochlorothiazide was given orally at the same time at a dosage of 5 mg/dose twice a day, and the dose was gradually reduced to discontinuation. The dose of hydrocortisone was gradually reduced until it was discontinued. After discontinuing hydrocortisone and diazoxide alone, the patient did not suffer from hypoglycemia or convulsions. The patient was discharged on postnatal day 25. The patients' medication and glycemic control levels during hospitalization and after discharge are shown in Table 2. TABLE 2Patients' medication and glycemic control levels during hospitalization and after hospital discharge.Postnatal timeDrug dosageGlucose infusion rate (mg/kg/min)Glucose control levels (reference range 2.5–5.0 mmol/L)43 h postnatal10% glucose 30 mL6.3Lowest 1.32–9 days postnatalHydrocortisone 7 mg q6h8–20 Lowest 1.3 before milk Lowest 3.1 after milk 10th day postnatal Diazoxide 5 mg/kg/d q8h Hydrocortisone 7 mg q12h 16–17 Lowest 1.8 before milk Lowest 2.3 after milk 11–15 days postnatalDiazoxide 5 mg/kg/d q8h11.5–16.82.2–5.616‐25 days postnatal* Diazoxide 10 mg/kg/d q8h4.0–11.5 (intravenous fluids were discontinued on postnatal day 22)3.8–6.52 m postnatal follow‐upDiazoxide 10 mg/kg/d q8h5.36 m postnatal follow‐upDiazoxide 10 mg/kg/d q8h5.112 m postnatal follow‐upDiazoxide 10 mg/kg/d q8h4.4*Patient discharged 25 days after admission. Patients' medication and glycemic control levels during hospitalization and after hospital discharge. Lowest 1.3 before milk Lowest 3.1 after milk Diazoxide 5 mg/kg/d q8h Hydrocortisone 7 mg q12h Lowest 1.8 before milk Lowest 2.3 after milk Patient discharged 25 days after admission. Outcome and Follow‐Up After discharge from the hospital, the patient was followed up in the Department of Endocrinology for 2, 6, and 12 months, and the serum insulin and C‐peptide levels were monitored to gradually return to normal (serum insulin was monitored at 192.89 pmol/L, C‐peptide level was 970.86 pmol/L, and glycosylated hemoglobin was 3.4 for 2 months after birth; serum insulin was monitored at 7.71 pmol/L, C‐peptide level was 142.21 pmol/L, blood ammonia was 134 umol/L, and glycated hemoglobin was 5.1 for 6 months after birth; for 12 months after birth, serum insulin was < 7.20 pmol/L, C‐peptide level was 89.71 pmol/L, blood ammonia was 156 umol/L, and glycated hemoglobin was 4.4), the patient's blood glucose remained stable, and no diazoxide dosage‐related adverse effects were seen. The patient was evaluated for 6 and 12 months by the health checkup in the child health epartment, with good growth, as normal children of the same age. At the age of 3 years and 2 months, the patient presented to the developmental‐behavioral clinic with stuttering for 6 months. Laboratory examinations showed insulin‐like growth factor‐1 (IGF‐1) 20.8 ng/mL (reference range 50–286 ng/mL), insulin‐like growth factor‐binding protein 3 (IGFBP‐3) 2.64 μg/mL (reference range 1.7–4.3 μg/mL), vitamin A 0.35 mg/L, and total 25‐hydroxyvitamin D 45.7 ng/mL. At the age of 3 years and 6 months, the patient visited the emergency department for sudden convulsions while awake, characterized by loss of consciousness, unresponsiveness, head retraction, upward gaze, cyanosis, limb rigidity and jerking, and urinary incontinence. The episode lasted 3–5 min and remitted spontaneously, followed by fatigue and sleep. Blood glucose during the seizure was 7.2 mmol/L. After admission, laboratory results were as follows: serum insulin 3.18 pmol/L, blood ammonia 93 μmol/L, glycated hemoglobin 4.9%, C‐peptide 230 pmol/L. Cranial MRI revealed multiple abnormal signals in the right frontal lobe and bilateral parietal lobes, suggestive of possible delayed myelination, with no obvious structural abnormalities. A 2‐h electroencephalogram was normal. No further seizures occurred after admission. At the age of 3 years and 8 months, the patient was seen in the neurology clinic for intermittent limb jerks during sleep. A 16‐h long‐term electroencephalogram was scheduled but not completed due to poor cooperation. Discussion Congenital hyperinsulinemia (CHI) varies in age of onset, biochemical features, and clinical manifestations depending on the genetics type. Four main genetic types have been identified so far: KATP‐type hyperinsulinemia (KATP‐HI), glutamate dehydrogenase hyperinsulinism (GDH‐HI), glucokinase‐type hyperinsulinemia (GCK‐HI), short‐chain 3‐hydroxyamino‐CoA dehydrogenase‐type hyperinsulinemia (SCHAD‐HI) [3, 10, 11, 12, 13]. Persistent or recurrent hypoglycemia and inappropriate insulin secretion in hypoglycemic states are important features of all types of CHI. Compared with other types of CHI, GDH‐HI has a wide age range of onset, with neonatal onset being rare, at an average age of 5–6 months [3, 12, 13]. To date, only one case of neonatal‐onset GDH‐HI with the variant G499C has been reported: the patient developed symptoms on the first day after birth, had a birth weight of 2.7 kg, carried a de novo variant c.1495C>A (p.G499C), presented with epileptic seizures and tics, and showed a favorable response to diazoxide treatment [6]. Patients carrying the G499C mutation presented with clinical manifestations within the first 48 h after birth, representing a life‐threatening condition for newborn infants. Comprehensive documentation of this mutation enables the implementation of timely diagnostic strategies and therapeutic interventions. The mode of inheritance for GDH‐HI is either autosomal dominant inheritance or de novo mutation, and de novo mutations account for about 80% [14]. The patient in this study had a de novo mutation, and the mode of inheritance was consistent with previous reports. Literature reports that 46%–64% of children with HI/HA can have epilepsy, and most of their mutations occur in exons 6 and 7 [3]. The patient in this study was sequenced by whole exome sequencing for a missense mutation in exon 12 region. The relationship between different mutation positions and genotype–phenotype remains to be investigated. The level of developmental delay associated with CHI usually correlates with the severity of hypoglycemia and the timeliness of controlling the episode. Therefore, early recognition and appropriate treatment are essential to avoid severe hypoglycemia‐related brain damage and long‐term neurological sequelae. Most researchers recommend maintaining blood glucose levels above 3.3 mmol/L (60 mg/dL), which is sufficient to prevent frequent episodes of neurologic hypoglycemia [5, 15, 16]. MRI of the patient indicated mild cerebral white matter edema, which was consistent with the imaging manifestations of hypoglycemic brain injury. Cerebral white matter is highly sensitive to energy deficiency; during hypoglycemia, cerebral cells develop energy metabolism disorders and subsequently present with cytotoxic edema, at which point the DWI sequence of MRI may show localized hyperintensity. Mild cerebral white matter edema suggests that cerebral cells are in a stage of reversible injury. Timely treatment measures such as intravenous glucose supplementation to correct hypoglycemia can prevent the progression of edema to irreversible white matter necrosis and malacia. Dynamic monitoring via MRI can be used to evaluate the outcome of cerebral white matter edema. Diazoxide, an ATP‐sensitive potassium channel opener, is the first choice and first‐line drug for the treatment of CHI [10, 11]. The starting dose of diazoxide is 5 mg/kg/d orally, and the dose is adjusted in the range of 5–15 mg/kg/d according to the results of blood glucose monitoring, with the maximum dose not exceeding 15 mg/kg/d. When an increase to the maximum dose is still ineffective, further increases in dose will also be ineffective and may result in serious complications. The half‐life of diazoxide in children is 9.5–24.0 h. Therefore, the efficacy of diazoxide should be assessed after at least 5 days of treatment [5]. An indicator of effective treatment with this drug is the maintenance of fasting blood glucose levels above 3.9 mmol/L. If there is no therapeutic effect after 2–3 weeks of treatment, discontinuation of diazoxide is recommended [17]. When drug therapy is effective, the maintenance dose does not need to be varied with body weight. Many clinical data suggest that diazoxide has a high safety profile and can be used for the long‐term treatment of diazoxide‐sensitive CHI [18]. Common side effects of diazoxide are sodium retention and hirsutism (which subsides after discontinuation of the drug). Sodium retention is common in the neonatal period and may lead to pulmonary hypertension and/or heart failure. Therefore, thiazide diuretics (e.g., hydrochlorothiazide 1–2 mg/kg/d orally 2–3 times daily) are usually combined with diazoxide in the neonatal period to prevent sodium retention. Mutations in the GLUD1 gene, which encodes glutamate dehydrogenase (GDH), are identified in patients with glutamate dehydrogenase‐related hyperinsulinism (GDH‐HI). In pancreatic, hepatic, and brain tissues, GDH is recognized as a key regulator of amino acid and ammonia metabolism. Under physiological conditions, GDH is activated by adenosine diphosphate (ADP) and leucine, whereas it is inhibited by guanosine triphosphate (GTP) and adenosine triphosphate (ATP). Mutations in the GLUD1 gene lead to reduced sensitivity of GDH to its allosteric inhibitor GTP, resulting in enhanced GDH activity. Glutamate is consumed by the hyperactivated GDH to generate large quantities of ammonia, thereby causing elevated blood ammonia levels. Therefore, asymptomatic persistent hyperammonemia is typically complicated in patients with GDH‐HI, in addition to hypoglycemia [19]. Hyperammonemia in GDH‐HI patients is mostly persistent without periodic fluctuations, and the blood ammonia level can reach 3–5 times the upper limit of the normal range (reference range: 9–30 μmol/L). In the present case, the patient's blood ammonia levels were detected as 108 μmol/L and 111 μmol/L on the 2nd and 8th day after admission, respectively; the maximum blood ammonia level was measured as 156 μmol/L during post‐discharge follow‐up. All these values were found to fall within the range reported in the literature, and the patient had no clinical symptoms related to hyperammonemia before the age of 2 years. Thus, we hypothesize that the development of such hyperammonemia may not be genetically specific. Among all the patients diagnosed with CHI, fewer cases of CHI caused by GLUD1 gene mutation were diagnosed in the neonatal period. In this study, the patient presented with severe hypoglycemia and convulsions 43 h after birth, and the diagnosis of HI/HA was confirmed by genetic testing. The clinical features were typical, and it was sensitive to the treatment of diazoxide. Based on the long‐term follow‐up data of this child, although his early growth and development were normal, he gradually developed neurodevelopmental manifestations including speech disorder (stuttering), afebrile convulsions, and limb jerks during sleep at the age of 3 years. Laboratory examinations indicated a significantly decreased serum IGF‐1 level with a normal IGFBP‐3 level, suggesting that the impaired growth and development were secondary to chronic metabolic disturbance and recurrent hypoglycemia. Cranial MRI showed multiple abnormal signals in the cerebral cortex, which were suggestive of possible delayed myelination. The results of this patient suggest that even if patients with hyperinsulinism‐hyperammonemia syndrome caused by GLUD1 mutation have favorable early development, they may gradually develop progressive neurodevelopmental sequelae. Recurrent hypoglycemia and chronic hyperammonemia may jointly lead to long‐term neurological damage and abnormal GH‐IGF axis function. Therefore, long‐term and systematic monitoring of blood glucose, blood ammonia, neurodevelopment, IGF‐1, IGFBP‐3, and electroencephalography is crucial for evaluating the long‐term prognosis of affected children. This study enriches the clinical and long‐term follow‐up data of patients with congenital hyperinsulinemia‐hyperammonemia syndrome diagnosed in the neonatal period and responsive to diazoxide treatment, providing important references for the clinical diagnosis and treatment of this disease. Author Contributions Tingyu Li: conceptualization, data curation, writing – original draft. Tianyi Liu: formal analysis, resources, software. Lujuan Li: investigation, methodology, validation. Yang Liu: methodology, software, validation, visualization. Qi Zhang: methodology, visualization. Xian Cheng: data curation, funding acquisition, project administration, writing – review and editing. Zhong Li: funding acquisition, project administration, supervision, writing – review and editing. Funding This work was supported by Science and Technology Innovation Foundation of Dalian (2023JJ13SN044). Dean's Fund of Dalian Women and Children's Medical Group (2024‐FEJT‐YZ‐24). Ethics Statement The study was approved by the Medical Ethics Committee of Dalian Women and Children's Medical Group (FEJT‐KY‐2024‐17). Written informed consent was obtained from the patient for publication of this case report. Conflicts of Interest The authors declare no conflicts of interest.